Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GAIN Is Great: Now Who Gets the Benefits?

This article was originally published in RPM Report

Executive Summary

Congress is set on enacting a package of antibiotic development incentives—but needs to sort out how best to define the targets.


Related Content

GAIN Begins (Part 1): FDA Completes Turnaround On Antibiotic R&D
The Limitations of Antibiotic Incentives
The Popularity of “Special Pop”: Antibiotics Incentives and PDUFA V
FDA Antibiotic Legislation Should Focus On Criteria, Not Bacteria, Woodcock Says
FDA Exploring Limited-Use Approvals For Antibiotics Based On Small Development Programs
GAIN Act Update: Antibiotic Pipeline Problem is Politically Ripe


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts